StreetInsider.com News Articles

Form 4 Alpha Cognition Inc. For: Jun 09 Filed by: Opaleye Management Inc.

Thu, 11 Jun 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260611/26635604.html

Form 4 Alpha Cognition Inc. For: Jun 09 Filed by: Opaleye Management Inc.

Thu, 11 Jun 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260611/26635604.html

Form 4 Alpha Cognition Inc. For: Jun 05 Filed by: Opaleye Management Inc.

Tue, 09 Jun 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260609/26623641.html

Form 4 Alpha Cognition Inc. For: Jun 05 Filed by: Opaleye Management Inc.

Tue, 09 Jun 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260609/26623641.html

Alpha Cognition reports study results for ZUNVEYL in Alzheimer's care

Tue, 09 Jun 2026 08:01:32 -0400

Alpha Cognition Inc. (NASDAQ: ACOG) announced results from its BEACON real-world study evaluating ZUNVEYL in long-term care residents with mild to moderate Alzheimer's disease. The retrospective observational study involved 21 investigators treating 162 patients who received ZUNVEYL for 3 to 12 months.

According to provider assessments, 92% of patients showed cognitive improvement following ZUNVEYL initiation. Providers reported improvement in neuropsychiatric symptoms in 93% of patients and delayed initiation or discontinuation of psychotropic medications in 80% of patients. Activities of daily living improved in 71% of patients, while sleep-related outcomes improved in 72% of patients.

The study examined patients who had received prior

Alpha Cognition reports study results for ZUNVEYL in Alzheimer's care

Tue, 09 Jun 2026 08:01:32 -0400

The study examined patients who had received prior

Alpha Cognition Reports Positive Top-Line Results from BEACON Real-World Study of ZUNVEYL® in Alzheimer’s Disease

Tue, 09 Jun 2026 08:00:00 -0400

In a retrospective observational study based on provider assessments and chart review:

Providers reported cognitive improvement in 92% of patients following initiation of ZUNVEYL
Providers reported improvement in neuropsychiatric symptoms in 93% of patients after initiation of ZUNVEYL
Providers reported delayed initiation or discontinuation of concomitant psychotropic medications in 80% of patients receiving ZUNVEYL
Providers reported favorable changes in activities of daily living (ADLs) in 71% of patients following initiation of ZUNVEYL
Providers reported improvements across sleep-related outcomes in 72% of patients following initiation of ZUNVEYL
Providers reported favorable gastrointestinal (GI) tolerability and overall treatment experience in patients receiving ZUNVEYL

VANCOUVER, British

Alpha Cognition Reports Positive Top-Line Results from BEACON Real-World Study of ZUNVEYL® in Alzheimer’s Disease

Tue, 09 Jun 2026 08:00:00 -0400

In a retrospective observational study based on provider assessments and chart review:

Providers reported cognitive improvement in 92% of patients following initiation of ZUNVEYL
Providers reported improvement in neuropsychiatric symptoms in 93% of patients after initiation of ZUNVEYL
Providers reported delayed initiation or discontinuation of concomitant psychotropic medications in 80% of patients receiving ZUNVEYL
Providers reported favorable changes in activities of daily living (ADLs) in 71% of patients following initiation of ZUNVEYL
Providers reported improvements across sleep-related outcomes in 72% of patients following initiation of ZUNVEYL
Providers reported favorable gastrointestinal (GI) tolerability and overall treatment experience in patients receiving ZUNVEYL

VANCOUVER, British

Alpha Cognition Reports Positive Top-Line Results from BEACON Real-World Study of ZUNVEYL® in Alzheimer’s Disease

Tue, 09 Jun 2026 08:00:00 -0400

In a retrospective observational study based on provider assessments and chart review:

Providers reported cognitive improvement in 92% of patients following initiation of ZUNVEYL
Providers reported improvement in neuropsychiatric symptoms in 93% of patients after initiation of ZUNVEYL
Providers reported delayed initiation or discontinuation of concomitant psychotropic medications in 80% of patients receiving ZUNVEYL
Providers reported favorable changes in activities of daily living (ADLs) in 71% of patients following initiation of ZUNVEYL
Providers reported improvements across sleep-related outcomes in 72% of patients following initiation of ZUNVEYL
Providers reported favorable gastrointestinal (GI) tolerability and overall treatment experience in patients receiving ZUNVEYL

VANCOUVER, British

Alpha Cognition Reports Positive Top-Line Results from BEACON Real-World Study of ZUNVEYL® in Alzheimer’s Disease

Tue, 09 Jun 2026 08:00:00 -0400

In a retrospective observational study based on provider assessments and chart review:

Providers reported cognitive improvement in 92% of patients following initiation of ZUNVEYL
Providers reported improvement in neuropsychiatric symptoms in 93% of patients after initiation of ZUNVEYL
Providers reported delayed initiation or discontinuation of concomitant psychotropic medications in 80% of patients receiving ZUNVEYL
Providers reported favorable changes in activities of daily living (ADLs) in 71% of patients following initiation of ZUNVEYL
Providers reported improvements across sleep-related outcomes in 72% of patients following initiation of ZUNVEYL
Providers reported favorable gastrointestinal (GI) tolerability and overall treatment experience in patients receiving ZUNVEYL

VANCOUVER, British

Form 4 Alpha Cognition Inc. For: May 27 Filed by: Opaleye Management Inc.

Fri, 29 May 2026 19:21:00 -0400

si-local-file:///var/storage/secattach/20260529/26576943.html

Form 4 Alpha Cognition Inc. For: May 27 Filed by: Opaleye Management Inc.

Fri, 29 May 2026 19:21:00 -0400

si-local-file:///var/storage/secattach/20260529/26576943.html

Maxim Group Starts Alpha Cognition Inc (ACOG) at Buy

Fri, 29 May 2026 07:38:15 -0400

Maxim Group analyst Naz Rahman initiates coverage on Alpha Cognition Inc (NASDAQ: ACOG) with a Buy rating and a price target of $12.00.

For an analyst ratings summary and ratings history on Alpha Cognition Inc click here. For more ratings news on Alpha Cognition Inc click here.

Shares of Alpha Cognition Inc closed at $5.94 yesterday.

Form SCHEDULE 13G/A Alpha Cognition Inc. Filed by: Opaleye Management Inc.

Fri, 22 May 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260522/26541528.html

Form SCHEDULE 13G/A Alpha Cognition Inc. Filed by: Opaleye Management Inc.

Fri, 22 May 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260522/26541528.html

Form 4 Alpha Cognition Inc. For: May 20 Filed by: Opaleye Management Inc.

Fri, 22 May 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260522/26541541.html

Form 4 Alpha Cognition Inc. For: May 20 Filed by: Opaleye Management Inc.

Fri, 22 May 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260522/26541541.html

Form 4 Alpha Cognition Inc. For: May 19 Filed by: D'Angelo Lauren

Tue, 19 May 2026 17:02:00 -0400

si-local-file:///var/storage/secattach/20260519/26522384.html

Form 4 Alpha Cognition Inc. For: May 19 Filed by: D'Angelo Lauren

Tue, 19 May 2026 17:02:00 -0400

si-local-file:///var/storage/secattach/20260519/26522384.html

Form 4 Alpha Cognition Inc. For: May 15 Filed by: Opaleye Management Inc.

Tue, 19 May 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260519/26521036.html

Form 4 Alpha Cognition Inc. For: May 15 Filed by: Opaleye Management Inc.

Tue, 19 May 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260519/26521036.html

Alpha Cognition (ACOG) Misses Q1 EPS by 32c

Thu, 14 May 2026 17:16:02 -0400

Alpha Cognition (NASDAQ: ACOG) reported Q1 EPS of ($0.32). Revenue for the quarter came in at $3.54 million.

For earnings history and earnings-related data on Alpha Cognition (ACOG) click here.

Alpha Cognition reports Q1 2026 ZUNVEYL revenue of $3.5M, up 40%

Thu, 14 May 2026 16:15:40 -0400

Alpha Cognition Inc. (NASDAQ: ACOG) reported first quarter 2026 net product revenue of $3.5 million for its Alzheimer's treatment ZUNVEYL, representing a 40% increase from the fourth quarter of 2025, according to a press release statement.

The biopharmaceutical company dispensed 6,054 bottles of ZUNVEYL in the first quarter, marking a 23% quarter-over-quarter increase. March represented the strongest demand month since the drug's launch, with approximately 29% growth over February.

Cumulative net product revenue for ZUNVEYL totaled $10.3 million through the first four full quarters since launch. The company reported that approximately 75% of prescribers and 81% of facilities demonstrated repeat utilization during

Alpha Cognition reports Q1 2026 ZUNVEYL revenue of $3.5M, up 40%

Thu, 14 May 2026 16:15:40 -0400

Alpha Cognition reports Q1 2026 ZUNVEYL revenue of $3.5M, up 40%

Thu, 14 May 2026 16:15:40 -0400